The content on this site is intended for healthcare professionals only
Prof Sebastien Giebel talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about transplant as a method of treating ALL patients.
Prof Giebel discusses some of the issues surrounding these transplants but how it is still a majorly popular course of treatment.
Prof Giebel also considers how to treat T-cell ALL and whether or not technological advances will alter the landscape for treatment in the near future.
He goes on to say that, if a transplant is needed, recent advancements mean a donor can be found for everyone.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Relapsed refractory multiple myeloma
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
IORT at the Asian Hospital and Medical Center
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
